In our last analysis we had identified the possibility off a breakout in SRPT, that has now come to fruition and has played out perfectly, this is a prime example of why you should analysis every company not just those highlighted on mainstream media. Such opportunities are easier to identify in larger time frames and produce mush greater gains, 24% gain in 4 days is difficult to beat. Happy investors.
AVERAGE ANALYSTS PRICE TARGET $204
AVERAGE ANALYSTS RECOMMENDATION BUY
P/E RATIO
SHORT INTEREST 15%
COMPANY PROFILE
Sarepta Therapeutics , Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
AVERAGE ANALYSTS PRICE TARGET $204
AVERAGE ANALYSTS RECOMMENDATION BUY
P/E RATIO
SHORT INTEREST 15%
COMPANY PROFILE
Sarepta Therapeutics , Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.